NKGen Biotech, Inc. (NKGN)
NASDAQ: NKGN · IEX Real-Time Price · USD
1.190
+0.080 (7.21%)
At close: Jul 19, 2024, 4:00 PM
1.150
-0.040 (-3.36%)
Pre-market: Jul 22, 2024, 7:22 AM EDT
Company Description
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies.
Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors.
The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.
NKGen Biotech, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Dr. Paul Y. Song M.D. |
Contact Details
Address: 3001 Daimler St, Santa Ana, California 92705 United States | |
| Phone | (949) 396-6830 |
| Website | grafacq.com |
Stock Details
| Ticker Symbol | NKGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001845459 |
| ISIN Number | US65488A1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul Y. Song M.D. | Chief Executive Officer and Chairman |
| Sangwoo Park | Executive Director |
| James A. Graf | Interim Chief Financial Officer |
| Pierre Gagnon | Chief Operating Officer |
| Yoonmi Kang | Vice President of Technical Operations |
| Dr. Yong Man Kim Ph.D. | Chief Scientific Officer |
| Denise A. Chua CLS, MBA, MT (ASCP) | Vice President of Investor Relations and Corporate Communications |
| Irene Chang | Vice President of Human Resources |
| Ryan Park C.F.A. | SVice President of Financial Planning and Analysis and Corporate Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | 8-K | Current Report |
| Jul 17, 2024 | 8-K | Current Report |
| Jul 12, 2024 | PRER14A | Filing |
| Jul 12, 2024 | 8-K | Current Report |
| Jul 10, 2024 | 424B3 | Prospectus |
| Jul 8, 2024 | EFFECT | Notice of Effectiveness |
| Jun 27, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 21, 2024 | 8-K | Current Report |
| May 20, 2024 | 10-Q | Quarterly Report |
| May 17, 2024 | PRE 14A | Other preliminary proxy statements |